These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22775)

  • 21. Theory of antimotion sickness drug mechanisms.
    Wood CD; Graybiel A
    Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925
    [No Abstract]   [Full Text] [Related]  

  • 22. [The adequacy of a new method for assessing the vestibular protective effect of biologically active substances].
    Karkishchenko NN; Dimitriadi NA
    Farmakol Toksikol; 1991; 54(5):14-6. PubMed ID: 1800137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of some effects of three antimotion sickness drugs on nystagmic responses to angular accelerations and to optokinetic stimuli.
    Collins WE; Schroeder DJ; Elam GW
    Aviat Space Environ Med; 1982 Dec; 53(12):1182-9. PubMed ID: 7159338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effective intensity of Coriolis, cross-coupling stimulation is gravitoinertial force dependent: implications for space motion sickness.
    Lackner JR; Graybiel A
    Aviat Space Environ Med; 1986 Mar; 57(3):229-35. PubMed ID: 3485968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antimotion sickness drugs.
    Wood CD; Graybiel A
    Otolaryngol Clin North Am; 1973 Feb; 6(1):301-13. PubMed ID: 4220285
    [No Abstract]   [Full Text] [Related]  

  • 26. Coriolis effects are principally caused by gyroscopic angular acceleration.
    Isu N; Yanagihara M; Mikuni T; Koo J
    Aviat Space Environ Med; 1994 Jul; 65(7):627-31. PubMed ID: 7945130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of phosphatidylcholine in the modulation of motion sickness susceptibility.
    Kohl RL; Ryan P; Homick JL
    Aviat Space Environ Med; 1985 Feb; 56(2):125-8. PubMed ID: 3985888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic control of vomiting.
    Davis LE
    J Am Vet Med Assoc; 1980 Feb; 176(3):241-2. PubMed ID: 7364635
    [No Abstract]   [Full Text] [Related]  

  • 29. Vertigo and motion sickness. Part II: Pharmacologic treatment.
    Zajonc TP; Roland PS
    Ear Nose Throat J; 2006 Jan; 85(1):25-35. PubMed ID: 16509240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The etiology and drug therapy of kinesia: investigations by means of the coriolis effect under cyclizine.
    Reicke N
    ORL J Otorhinolaryngol Relat Spec; 1976; 38(5):267-75. PubMed ID: 1087393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs used in vomiting.
    Br Med J; 1970 Feb; 1(5694):481-3. PubMed ID: 4392220
    [No Abstract]   [Full Text] [Related]  

  • 32. [An experimental validation of pharmacological agents to arrest the vestibulo-autonomic syndrome (motion sickness)].
    Shashkov VS; Kotovskaia AR; Orlov OI; Koloteva MI; Shashkov AV; Karsanova SK
    Eksp Klin Farmakol; 1999; 62(6):11-5. PubMed ID: 10650518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prevention of motion sickness in orbital flight.
    Graybiel A
    Life Sci Space Res; 1976; 14():109-18. PubMed ID: 11977268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats.
    Takeda N; Hasegawa S; Morita M; Horii A; Uno A; Yamatodani A; Matsunaga T
    Methods Find Exp Clin Pharmacol; 1995 Nov; 17(9):589-90. PubMed ID: 8786672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
    Wood CD; Stewart JJ; Wood MJ; Manno JE; Manno BR; Mims ME
    Aviat Space Environ Med; 1990 Feb; 61(2):157-61. PubMed ID: 2178599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. NSAM-945.
    Wood CD; Graybiel A; Kennedy RS
    Res Rep U S Nav Sch Aviat Med; 1965 Jul; ():1-9. PubMed ID: 5322559
    [No Abstract]   [Full Text] [Related]  

  • 38. The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness.
    Levine ME; Chillas JC; Stern RM; Knox GW
    Aviat Space Environ Med; 2000 Nov; 71(11):1111-4. PubMed ID: 11086664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suncus murinus as a new experimental model for motion sickness.
    Ueno S; Matsuki N; Saito H
    Life Sci; 1988; 43(5):413-20. PubMed ID: 2899827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.